RAPAGEN Trademark

Trademark Overview

On Monday, February 9, 2015, a trademark application was filed for RAPAGEN with the United States Patent and Trademark Office. The USPTO has given the RAPAGEN trademark a serial number of 86528633. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 1, 2018. This trademark is owned by Vascular Therapies, Inc.. The RAPAGEN trademark is filed in the Pharmaceutical Products category with the following description:

A combination drug product, namely, a formulation of sirolimus incorporated within a collagen membrane, which, as an implantable drug carrier, enables local delivery of sirolimus to the vascular wall
rapagen

General Information

Serial Number86528633
Word MarkRAPAGEN
Filing DateMonday, February 9, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 1, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 30, 2015

Trademark Statements

Goods and ServicesA combination drug product, namely, a formulation of sirolimus incorporated within a collagen membrane, which, as an implantable drug carrier, enables local delivery of sirolimus to the vascular wall

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 23, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameVascular Therapies, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCresskill, NJ 07626
Party NameVascular Therapies, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCresskill, NJ 07626

Trademark Events

Event DateEvent Description
Monday, October 1, 2018ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 1, 2018ABANDONMENT - NO USE STATEMENT FILED
Friday, March 2, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 1, 2018EXTENSION 5 GRANTED
Friday, February 23, 2018EXTENSION 5 FILED
Monday, February 26, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 23, 2018TEAS EXTENSION RECEIVED
Saturday, August 19, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 17, 2017EXTENSION 4 GRANTED
Thursday, August 17, 2017EXTENSION 4 FILED
Thursday, August 17, 2017TEAS EXTENSION RECEIVED
Saturday, February 11, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 9, 2017EXTENSION 3 GRANTED
Thursday, February 9, 2017EXTENSION 3 FILED
Thursday, February 9, 2017TEAS EXTENSION RECEIVED
Tuesday, September 20, 2016ASSIGNED TO EXAMINER
Tuesday, September 13, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 12, 2016EXTENSION 2 GRANTED
Tuesday, August 2, 2016EXTENSION 2 FILED
Thursday, August 25, 2016CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 2, 2016TEAS EXTENSION RECEIVED
Tuesday, February 23, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 19, 2016EXTENSION 1 GRANTED
Friday, February 19, 2016EXTENSION 1 FILED
Friday, February 19, 2016TEAS EXTENSION RECEIVED
Tuesday, August 25, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 30, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 30, 2015PUBLISHED FOR OPPOSITION
Wednesday, June 10, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 19, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 14, 2015ASSIGNED TO EXAMINER
Monday, February 23, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, February 12, 2015NEW APPLICATION ENTERED IN TRAM

Related Keywords

rapagen sirolimus drug enables implantable local carrier delivery wall vascular which